BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14616808)

  • 1. Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients.
    Bianchi L; Costanzo A; Campione E; Nisticò S; Chimenti S
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():24-6. PubMed ID: 14616808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.
    Kagy MK; Amonette R
    Dermatol Surg; 2000 Jun; 26(6):577-8; discussion 578-9. PubMed ID: 10848940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.
    Mirza B; De'Ambrosis B
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():16-8. PubMed ID: 14616806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
    Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
    Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome.
    Micali G; Lacarrubba F; Nasca MR; De Pasquale R
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():19-23. PubMed ID: 14616807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes.
    Quatresooz P; Piérard GE
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():27-9. PubMed ID: 14616809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.
    Geisse J; Caro I; Lindholm J; Golitz L; Stampone P; Owens M
    J Am Acad Dermatol; 2004 May; 50(5):722-33. PubMed ID: 15097956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study.
    van der Geer S; Martens J; van Roij J; Brand E; Ostertag JU; Verhaegh ME; Neumann HA; Krekels GA
    Br J Dermatol; 2012 Jul; 167(1):110-5. PubMed ID: 22385074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
    Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
    Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas.
    Nikkels AF; Piérard-Franchimont C; Nikkels-Tassoudji N; Bourguignon R; Piérard GE
    Acta Clin Belg; 2005; 60(5):227-34. PubMed ID: 16398319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cutaneous tumors with topical 5% imiquimod cream.
    Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
    Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
    Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
    Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream.
    Cowen E; Mercurio MG; Gaspari AA
    J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S240-8. PubMed ID: 12271286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superficial basal cell carcinoma on face treated with 5% imiquimod cream.
    Malhotra AK; Bansal A; Mridha AR; Khaitan BK; Verma KK
    Indian J Dermatol Venereol Leprol; 2006; 72(5):373-5. PubMed ID: 17050935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
    Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
    Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
    Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
    Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.